Your session is about to expire
← Back to Search
Carboplatin + Atezolizumab for Stage IV Triple Negative Breast Cancer
Study Summary
This trial is testing whether carboplatin works better with or without atezolizumab to treat patients with stage IV triple negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My hemoglobin level is at least 9.0 g/dL, with or without treatment.My bilirubin levels are within the limit, considering I have liver metastases.My cancer is not driven by estrogen or progesterone.I am willing to have a biopsy of my cancer that has spread.My alkaline phosphatase levels are within the limit, considering my liver metastases.I have a serious heart condition.My cancer is not driven by estrogen or progesterone.I have not had a severe infection needing treatment in the last 4 weeks.I have active tuberculosis.I have not received a live vaccine in the last 4 weeks.I have previously been treated with specific immune-targeting cancer drugs.My white blood cell count is healthy without needing medication in the last 2 weeks.I am fully active or can carry out light work.My breast cancer is stage IV and lacks ER, PR, and HER2 receptors.My liver function tests are within the required range.I have untreated or worsening spinal cord compression due to cancer.My brain or spinal cord cancer does not meet certain criteria.I have not had major surgery in the last 4 weeks.I am allergic to certain medications made in Chinese hamster ovary cells or any part of atezolizumab.I haven't taken any immune-boosting drugs in the last 4 weeks or five half-lives of the drug.My cancer is HER2 negative based on specific test results.I am willing to have a biopsy of my cancer that has spread if it's in an accessible place.I have had at most one chemotherapy treatment for my advanced cancer.My cancer has spread to the lining of my brain and spinal cord.I have active hepatitis B or C.You must give written permission after fully understanding the details of the study.My cancer causes me severe pain that isn't managed well.You have experienced severe reactions to certain types of medication called chimeric or humanized antibodies or fusion proteins in the past.I do not have any uncontrolled serious illnesses.I have high calcium levels in my blood that are causing symptoms.I am considered postmenopausal based on my age and hormone levels.I have never been treated with carboplatin.You are undergoing cancer treatment that is not allowed in this study.My cancer is not HER2 positive according to the latest tests.I have a history of lung scarring or currently have lung inflammation.I haven't taken steroids or immunosuppressants in the last 2 weeks.You have a history of autoimmune disease.I have not had any cancer other than triple-negative breast cancer in the last 5 years.You have enough lymphocytes (a type of white blood cell) in your blood.I am fully active or can carry out light work.You have a visible or measurable tumor that can be accurately measured using a specific method called RECIST criteria version 1.1.You have received an organ or stem cell transplant in the past.
- Group 1: Arm 2 (atezolizumab, carboplatin)
- Group 2: Arm 1 (atezolizumab, carboplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the usual purpose for running a Laboratory Biomarker?
"The laboratory biomarker is most frequently used to treat advanced thymoma, but it can also be effective for small cell lung cancer (sclc), advanced testicular cancer, and carcinoma, neuroendocrine."
Are there any other ongoing experiments that use Laboratory Biomarker?
"Laboratory Biomarker was first researched in 2002 at H Central de Asturias. Since that time, there have been 1015 completed trials and 1027 active clinical trials. Many of these are based out of Philadelphia, Pennsylvania."
How many patients are in this clinical trial?
"Unfortunately, this study is no longer looking for new participants. The trial was first posted on 8/29/2017 and ended on 8/31/2022. However, there are currently 2445 other studies searching for patients with triple negative breast neoplasms and 1027 Laboratory Biomarker studies that are still enrolling individuals."
Are investigators still looking for new participants for this trial?
"Unfortunately, this particular clinical trial is not presently enrolling patients. The listing on clinicaltrials.gov reflects that this study was posted on 8/29/2017 and was last edited on 8/31/2022; however, there are other trials recruiting participants right now--3,472 to be exact."
In how many different medical clinics is this trial currently taking place?
"University of Pennsylvania in Philadelphia, Indiana University Health Melvin Bren Simon Cancer Center in Indianapolis, Georgetown University Lombardi Comprehensive Cancer Center in Washington D.C., and 6 other locations are currently recruiting patients for this trial."
Is Laboratory Biomarker accepted by the FDA?
"There is some supporting data for the safety of this laboratory biomarker, but none yet for efficacy. Consequently, our team has tentatively rated it as a 2."
Share this study with friends
Copy Link
Messenger